- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03862872
Effects of Bend Beauty's Anti-Aging Formula on Inflammatory Markers (BENCHMARK)
The Effects of Oral Supplementation With Bend Beauty's Anti-Aging Formula on Inflammatory Markers
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a phase IV, randomized, double-blind, placebo-controlled, three-arm, parallel intervention study including three groups of 25 subjects between 35-65 years of age, treated with either Bend Beauty's Anti-Aging Formula, fish oil control or inert placebo for 90 days, with testing points at baseline, 30, 60, and 90 days.
Subjects will be preselected through a Subject Eligibility Screening (SES) against defined inclusion and exclusion criteria for entry into the trial. Eligible participants will be tested using the Chronic Inflammation Test for urinary 11-dehydrothromboxane B2 (https://chronicinflammationtest.com) and the Omega-3 Index Test for eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in red blood cells (RBC) (https://omegaquant.com ), to confirm possible presence of chronic inflammation. If these test results meet a defined limit, participants will be enrolled in the trial.
A number of assessments will be conducted before and after treatment.
Tipo di studio
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3Z 2J6
- Cornerstone Naturopathic Clinic, 14 Old School Rd, Upper Tantallon
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Provision of a signed and dated informed consent form (ICF)
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 35-65 years
- Subjects with Omega-3 Index of 5 or less.
- Subjects with Chronic Inflammation Scores of 415 or greater.
Exclusion Criteria:
- Subjects who are unwilling to provide blood and urine samples during the initial and subsequent test points.
- Subjects that have consumed Anti-Aging Formula, omega-3 fatty acid (i.e. fish oil, krill oil, algal oil), lutein, zeaxanthin, carotenoids, GLA (borage or evening primrose oils) and/or Vitamin D supplements during the last 3 months
- Subjects who were ill (i.e. rhino virus, influenza, etc.) within two weeks prior to the study start, or who have any active systemic infection (infected tooth, bladder infection, sinus infection, etc.)
Subjects taking:
- Anti-inflammatory medications including the nonsteroidal anti-inflammatory drugs (NSAID), cyclooxygenase (COX)-1 and COX-2 inhibitors, such as aspirin, ibuprofen (Advil and Voltaren), and naproxen, and acetaminophen (Tylenol®), either routinely or during the 7 days before baseline urine and blood testing.
- H2 antagonist/blockers [e.g. cimetidine (Tagamet®), ranitidine (Zantac®)]
- Anti-histamines [e.g. fexofenadine (Allegra®), terfenadine (Seldane®), diphenhydramine (Benadryl®), desloratadine (Clarinex®)], either routinely or during the 7 days before baseline urine and blood testing.
- Statins [e.g. atorvastatin (Lipitor®), lovastatin (Altoprev®), pitavastatin (Livalo®), pravastatin (Pravachol®), rosuvastatin (Crestor®), simvastatin (Zocor®)]
- Cannabinoids/Cannabis
Corticosteroids including:
- Inhaled treatments such as beclomethasone (QVAR®), budesonide (Pulmicort®), ciclesonide (Alvesco®), fluticasone (Flovent®), mometasone (Asmanex Twisthaler®)
- Oral treatments such as Prednisone
- Injectables such as cortisone injections and IV treatments such as Humira®, Enbrel® and Remicade®
- Topical treatments such as hydrocortisone (Anusol®)
- Subjects with known allergy or intolerance to the test material ingredients (i.e. fish, soy)
- Subjects who consume fish more than twice per week
- Subjects who smoke tobacco and/or cannabis products
- Women who are pregnant or are planning to become pregnant or are lactating during the course of the study
- Subjects who have participated in a clinical trial (CT) within the past 3 months
- Subjects living in the same household as subjects that are currently enrolled within this study
- Subjects with diabetes (or taking Metformin), diagnosed arthritis, diagnosed chronic kidney disease, cancer, or with any apparent acute injury inflammation (e.g. torn rotator cuff, broken leg, severe skin abrasions).
- Subject who consume alcohol during the 12 hours before baseline urine and blood testing
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Anti-Aging Formula
4 capsules daily of high-EPA fish oil, borage oil, zeaxanthin, lutein and vitamin D providing 1050 mg of Eicosapentaenoic acid (EPA) and 350 mg of Docosahexaenoic acid (DHA), 120 mg of Gamma-linolenic acid (GLA), 2.5 mg of zeaxanthin, 5 mg of lutein and 25 μg (1000 IU) of vitamin D3 for 90 days.
|
Anti-Aging Formula contains 1050 mg of EPA and 350 mg of DHA from anchovies, sardines, and/or mackerel whole body oil, 120 mg of GLA from Borage (Borago officianalis) seeds, 2.5 mg of zeaxanthin from Capsicum annuum L. fruit, 5 mg of lutein from Tagetes erecta flower, and 25 μg (1000 IU) of vitamin D3 (cholecalciferol) from lanolin per 4 capsule daily dose.
This dosage form is the same as is commercially marketed in Canada under license Natural Product Number (NPN) 80077254.
Altri nomi:
|
Comparatore attivo: Control Fish Oil
4 capsules daily of 1,106 mg each of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil providing 816 mg EPA and 572 mg DHA total for 90 days.
|
The control fish oil is a soft gelatin capsule containing 1,106 mg of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil.
A four capsule per day dose provides 816 mg EPA and 572 mg DHA, which is only slightly less EPA+DHA than is provided within a four capsule per day dose of Anti-Aging Formula.
This minor difference would not be expected to alter clinical outcomes.
|
Comparatore placebo: Inert Placebo
4 capsules daily of 1040 mg each of corn oil for 90 days.
|
The inert placebo is a soft gelatin capsule containing 1040 mg of corn oil.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Urinary 1-dehydrothromboxane B2 using The Chronic Inflammation Test
Lasso di tempo: Baseline to 90 days
|
The concentration of 1-dehydrothromboxane B2 in urine using The Chronic Inflammation Test (https://chronicinflammationtest.com) after treatment with Anti-Aging Formula, control fish oil and inert placebo.
|
Baseline to 90 days
|
Omega-3 Index
Lasso di tempo: Baseline to 90 days
|
The concentration of EPA+DHA expressed as the Omega-3 index (https://omegaquant.com), after treatment with Anti-Aging Formula, control fish oil and inert placebo
|
Baseline to 90 days
|
Urinary 8-hydroxy-2' -deoxyguanosine (8- OHdG)
Lasso di tempo: Baseline to 90 days
|
The concentration of 8-OHdG in urine after treatment with Anti-Aging Formula, control fish oil and inert placebo.
|
Baseline to 90 days
|
Urinary 8-isoprostane
Lasso di tempo: Baseline to 90 days
|
The concentration of 8-isoprostane in urine after treatment with Anti-Aging Formula, control fish oil and inert placebo.
|
Baseline to 90 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Blood pressure
Lasso di tempo: Baseline to 90 days
|
Blood pressure reported as mmHg (Systolic/Diastolic) after treatment with Anti-Aging Formula, control fish oil and inert placebo.
|
Baseline to 90 days
|
Resting heart rate
Lasso di tempo: Baseline to 90 days
|
Resting heart rate in beats per minute after treatment with Anti-Aging Formula, control fish oil and inert placebo.
|
Baseline to 90 days
|
Height
Lasso di tempo: Baseline to 90 Days
|
Height in meters (m) after treatment with Anti-Aging Formula, control fish oil and inert placebo.
|
Baseline to 90 Days
|
Weight
Lasso di tempo: Baseline to 90 days
|
Weight in Kilograms (Kg) after treatment with Anti-Aging Formula, control fish oil and inert placebo.
|
Baseline to 90 days
|
Body Mass Index (BMI)
Lasso di tempo: Baseline to 90 days
|
Weight and height will be combined to calculate BMI as kg/m2 after treatment with Anti-Aging Formula, control fish oil and inert placebo.
|
Baseline to 90 days
|
General health/function
Lasso di tempo: Baseline to 90 days
|
Subjective assessment of general health/function using an in-house designed questionnaire after treatment with Anti-Aging Formula, control fish oil and inert placebo. The questionnaire consists of a list of 27 questions with answers on a scale from 0-4 that cover a variety of health indicators including pain, task oriented performance, mental and emotional well-being, appetite, etc. The resulting score defines General Health/Function as
|
Baseline to 90 days
|
Physical activity rating
Lasso di tempo: Baseline to 90 days
|
Subjective assessment of physical activity using an in-house designed questionnaire after treatment with Anti-Aging Formula, control fish oil and inert placebo.
Results are expressed as how many days per week (0-7) that the Subject exercised to a defined amount, where a greater number of days is considered better.
|
Baseline to 90 days
|
Perceived health status
Lasso di tempo: Baseline to 90 days
|
Subjective assessment of perceived health using an in-house designed questionnaire after treatment with Anti-Aging Formula, control fish oil and inert placebo.
The results are expressed as the subjects' perceived health (degrees of good or bad) on the day that the questionnaire is completed using a scale of 0-100 where 0 is the worst imaginable health and 100 is the best imaginable health.
|
Baseline to 90 days
|
Mental well-being/depression
Lasso di tempo: Baseline to 90 days
|
Subjective assessment of mental well-being/depression using the Patient Health Questionnaire-9 after treatment with Anti-Aging Formula, control fish oil and inert placebo.
The Patient Health Questionnaire-9 is available in the public domain, and is employed to capture data more focused on mental health indicators of depression.
It is a version of the PRIME-MD diagnostic instrument for common mental disorders, which scores each of the nine DSM-IV criteria as "0" (not at all) to "3" (nearly every day).
It has been validated for use in primary care to monitor severity of depression and response to treatment.
Results are presented as a score ranging from 0-27, where 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, and 20-27 is severe depression.
|
Baseline to 90 days
|
Skin Condition
Lasso di tempo: Baseline to 90 days
|
Subjective assessment of skin condition using Observ 520 Skin Analysis (http://www.observ.uk.com/) after treatment with Anti-Aging Formula, control fish oil and inert placebo.
Observ 520 Skin Analysis measures skin condition in the epidermal and dermal layers using skin fluorescence and polarized light illumination technology to produce visual indicators of skin's condition.The technology allows overlay of one photo on top of another to enable comparative changes before and after treatment.
Numerical data will be created by comparing before and after treatment photos and assigning the descriptors: "improved", "unchanged", or "worsened" that correspond to the values +1, 0, or -1, respectively.
The average numerical value from each of the three treatment arms will then be calculated and compared, which will be used as quantitative measures of the treatments' effects on skin condition.
|
Baseline to 90 days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Ben Connolly, ND, BSc., Cornerstone Naturopathic Clinic
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- Infiammazione
- Vitamina D
- Pelle
- Acido eicosapentaenoico (EPA)
- Acido docosaesaenoico (DHA)
- Olio di pesce
- Marcatori infiammatori
- Luteina
- Zeaxantina
- 8-isoprostane
- Olio di borragine
- Luce UV
- Indice di Omega-3
- Gamma-linolenic acid (GLA)
- Chronic Inflammation Test
- 11-dehydrothromboxane B2
- 8-hydroxy-2' -deoxyguanosine (8- OHdG)
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CT1801
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Anti-Aging Formula
-
Oregon Research InstituteAttivo, non reclutanteCompromissione cognitiva lieveStati Uniti
-
University of Illinois at ChicagoNational Institute on Aging (NIA)ReclutamentoMalattie cardiache (malattia coronarica, cardiopatia ischemica, cardiopatia ipertensiva) | Diabete non controllato (HBA1c ≥ 10)Stati Uniti
-
Case Comprehensive Cancer CenterReclutamentoLinfoma | Mieloma | Complicazioni del trapianto di cellule staminali | Trapianto di cellule staminali allogeniche e autologheStati Uniti
-
Johns Hopkins UniversityTerminatoDegenerazione maculare umida | Degenerazione maculare legata all'età neovascolare | Emorragia sottomaculareStati Uniti
-
University of LeipzigSconosciutoEdema maculare diabetico | Edema maculare | Occlusione della vena retinicaGermania
-
Beijing Doing Biomedical Co., Ltd.Non ancora reclutamentoLinfoma | LeucemiaCina
-
George Washington UniversityNational Institutes of Health (NIH)ReclutamentoUso del tabaccoStati Uniti
-
Symphogen A/SCompletatoLinfoma | Tumore solido | Cancro metastaticoCanada, Stati Uniti
-
Shanghai Huaota Biopharmaceutical Co., Ltd.ReclutamentoNSCLC | Tumore solido avanzatoStati Uniti, Cina
-
The First Affiliated Hospital of Soochow UniversityReclutamento